WESTLAKE VILLAGE, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York.
|Event:||Goldman Sachs US Emerging / SMID Cap Growth Conference|
|Date:||Thursday, November 20, 2014|
|Time:||1:40 p.m. ET|
A live webcast will be available under the Investors section of the Company's website at www.kytherabiopharma.com. The presentation will be archived on the website and will be available for at least 14 days.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA's product candidate, ATX-101, is currently in late-stage clinical development for the reduction of submental fat, which commonly presents as a double chin, and is a potential first-in-class submental contouring injectable drug. KYTHERA submitted its New Drug Application for ATX-101 in May 2014, which the FDA has determined will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 13, 2015. KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
CONTACT: Investor Contact: Heather Rowe, Director, Investor Relations Tel: (818) 587-4559 email@example.com
Source:KYTHERA Biopharmaceuticals, Inc.